• Pfizer Inc., of New York, reported top-line results from the Phase III ORAL Start study of JAK inhibitor tofacitinib in moderate to severe active rheumatoid arthritis (RA). Data showed that the drug met the primary endpoints at both the 5-mg and 10-mg twice-daily doses. Tofacitinib was found to be superior to methotrexate, with statistically significant changes shown in inhibiting structural damage, as measured by change from baseline in modified Total Share Score, and in reducing signs and symptoms of RA, as measured by ACR70 responses. Both primary endpoints assessed tofacitinib vs. methotrexate at six months. The data are from a planned analysis at one year.